Cargando…
The efficacy and safety of varenicline nasal spray for the management of dry eye signs: a systematic review and meta-analysis
BACKGROUND: Dry eye disease (DED) is caused by a persistently unstable tear film leading to ocular discomfort and is treated mainly with tear supplementation. There is emerging evidence that nicotinic acetylcholine receptor (nAChR) agonists (e.g., varenicline and simpinicline) nasal sprays are effec...
Autores principales: | Bashrahil, Bader, Taher, Nada, Alzahrani, Ziyad, Alnabihi, Ahmed, Aldahlawi, Abdulaziz, Alkhathlan, Mohammed, Alghamdi, Saeed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347795/ https://www.ncbi.nlm.nih.gov/pubmed/37452334 http://dx.doi.org/10.1186/s12886-023-03069-y |
Ejemplares similares
-
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease
por: Frampton, James E.
Publicado: (2022) -
Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?
por: Sheppard, John D., et al.
Publicado: (2023) -
Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease
por: Hauswirth, Scott G, et al.
Publicado: (2023) -
ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
por: Wirta, David, et al.
Publicado: (2022) -
OC-01 (Varenicline Solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2
por: Schallhorn, Julie M, et al.
Publicado: (2023)